[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.153.73.72. Please contact the publisher to request reinstatement.
[Skip to Content Landing]

Should Physicians Consider the Environmental Effects of Prescribing Antibiotics?

Learning Objectives:
At the end of this activity, you will be able to:
1. Explain a new or unfamiliar viewpoint on a topic of ethical or professional conduct
2. Evaluate the usefulness of this information for his or her practice, teaching, or conduct
3. Decide whether and when to apply the new information to his or her practice, teaching, or conduct
1 Credit CME

The AMA Journal of Ethics exists to help medical students, physicians and all health care professionals navigate ethical decisions in service to patients and society. The journal publishes cases and expert commentary, medical education articles, policy discussions, peer-reviewed articles for journal-based and audio CME, visuals, and more. Learn more

Abstract

Pharmaceuticals are beginning to receive attention as a source of pollution in aquatic environments. Yet the impact of physician prescription patterns on water resources is not often discussed in clinical decision making. Here, we comment on a case in which empiric antibiotic treatment might benefit a patient while simultaneously being detrimental to the aquatic environment. We first highlight the potential harm caused by this prescription from its production to its disposal. We then suggest that Van Rensselaer Potter's original conceptualization of bioethics can be used to balance clinicians' obligations to protect individual, public, and environmental health.

Case

Dr. Turner, a hospitalist, is called to assess Mr. Johnson, an elderly patient with a history of urinary tract infections (UTIs), who presented to the ER with altered mental status. Urine cultures are pending but previous cultures have grown Escherichia coli (E. coli) with an extended-spectrum beta-lactamase (ESBL) gene. Although Mr. Johnson improves with intravenous fluids, Dr. Turner plans to treat Mr. Johnson with ciprofloxacin, a broad-spectrum fluoroquinolone-class antibiotic, to cover the E. coli that he has grown in the past. Dr. Turner recently read that this drug can persist, unaltered, in the hospital's wastewater collection system and in the municipal wastewater water treatment plant (WWTP). While much will be filtered, a quantifiable amount will end up in Mr. Johnson's local watershed. How should Dr. Turner, other physicians, and their institutions weigh the benefits that individual patients derive from pharmaceutical treatment with the contamination risk this treatment poses to freshwater resources used by entire communities and ecosystems?

Commentary

Production and disposal of antibiotics, and their impact on water supplies, is often overlooked in health care. Quiz Ref IDThe AMA Code of Medical Ethics focuses primarily on a physician's responsibility to her patient, whose autonomy (or her surrogate's) can only be superseded in special circumstances for public health 1,2 or when required by law 3.Quiz Ref IDIn terms of public health, pharmaceuticals pose well-known threats to water quality, most famously documented in the feminization of fish in the United Kingdom 4, but also in the increasing spread of antibiotic resistance in surface waters 5. In this paper, we trace the impact of ciprofloxacin from its production to its disposal to shed light on the ethical dilemmas posed by antibiotic contamination of aquatic environments. While a clinician's duty to meet the needs of her patients is undeniable, these needs must be balanced with a moral imperative to minimize the impact of antibiotics on the environment and on other community members, including future generations.

Pollution of Aquatic Environments

The ciprofloxacin prescribed to Mr. Johnson is a synthetic fluoroquinolone antibiotic 6. In the US, the Food and Drug Administration (FDA) places limits on the oxygen demand and solid sediment allowed in wastewater produced during pharmaceutical manufacturing 7. However, these regulations do not prevent the release of pharmaceuticals into surface water. Trace amounts of at least 82 pharmaceuticals and other organic wastewater contaminants are present in streams across the US 8. In India, where 39 percent of pharmaceutical plants that manufacture domestically consumed drugs are located, fluoroquinolone levels toxic to plants, algae, and bacteria have been found in wastewater discharged from drug manufacturers 9,11. Antibiotic-resistant bacteria such as ESBL gram-negative bacteria and carbapenem-resistant Enterobacteriaceae have been found in surface waters and tap water in the same region 12. Given the ease with which antibiotic-resistant genes can traverse continents, we must consider the global impacts of antibiotic production and effluent 13.

Locally, administration of Mr. Johnson's ciprofloxacin has a direct impact on his community. Quiz Ref IDClassified as a nonhazardous waste, extra amounts of ciprofloxacin mixed by Mr. Johnson's (or any) pharmacist can be discarded down a common drain 14. Once administered, up to 92 percent of the drug will be excreted unchanged in urine and feces 15. It will join other ecotoxic contrast materials, antihypertensives, and synthetic hormones on their way to the WWTP 16.

Harm to Human and Environmental Health

Harm to human health. Quiz Ref IDWhile some antibiotics are removed during wastewater treatment, many are discharged into receiving surface waters or deposited on soils in the form of sludge 5,17. Multiple studies have found antibiotics and antibiotic-resistant bacteria such as ESBL E. colidownstream of hospitals and local WWTPs 18,23, likely contributing to the epidemiology of antibiotic resistance 20. Current research has yet to demonstrate a direct link between wastewater and human infections, but resistant bacteria in streams and soil can be taken up by crops, livestock, or humans 24. Although the exact route of infection has not been established, there are several possible mechanisms. These microbes might be ingested through direct contact with streams or through the crops themselves, either causing immediate illness or colonizing a person's gastrointestinal tract 25. If a person later becomes sick from this microbiota, he or she could already be resistant to antibiotic treatment.

Harm to the environment. Fluoroquinolones and sulfonamides have been shown to interfere with nitrogen processing in the environment, leading to buildup of harmful nitrogen and resultant toxicity to nonhuman species 26,27. The predicted aquatic concentrations of amoxicillin and oxytetracycline released from WWTP annually in England exceed limits that are toxic to aquatic ecosystems 28. Quiz Ref IDAlthough direct harm to vertebrates from environmental antibiotic exposure is challenging to measure, pharmaceuticals in the environment can be carcinogenic, sterilizing, or fatal to species ranging from microbiota to rainbow trout 29. These changes also contribute to loss of biodiversity 30.

Ethical Dilemmas and the Origins of Bioethics

Two ethical dilemmas are posed by prescribing empiric antibiotics to Mr. Johnson: (1) do the benefits that he derives as an individual outweigh the harm his prescription poses to the environment; and (2) do these benefits justify the consequences of antibiotic resistance and decreased water quality for other community members, including future generations?

To approach the dilemmas above, we can turn to the original conceptualization of bioethics as a tool for decision making. In 1970, Van Rensselaer Potter introduced the term bioethics31. He argued that human survival depended on adequate resource allocation and that ethics should prioritize our ecological support systems 32. Potter's bioethics was not widely adopted and the term came to describe biomedical ethics 31,33. This form of ethics has traditionally been limited to individual patients and clinicians while environmental ethics focuses on the broader ecology and includes regard for sustainability as an ethical and not just a biological value 33. Common ground exists in both fields to preserve resources and prevent the spread of disease 33.

Individual benefit versus environmental harm. If Mr. Johnson truly had a UTI, morbidity can include nephrolithiasis (kidney stone), pyelonephritis (kidney infection), and urosepsis (bloodstream infection). Moreover, delays in antibiotic therapy have been shown to increase mortality 34. However, without observable signs or symptoms of these complications, the individual benefits could be small compared to the harms to the environment if all patients in Mr. Johnson's situation received antibiotics. In the US in 2014, about 21 million prescriptions were written for ciprofloxacin alone 35. The CDC estimates that up to 30 percent of outpatient antibiotic prescriptions are unnecessary, including those which would have been prescribed for suspected UTI 36. This magnitude of unnecessary antibiotic prescriptions demands intervention at the prescriber, institutional, and national level.

Individual benefit versus community harm. Clinicians and institutions can incorporate existing tools, such as the Treat Systems decision-support system (TREAT model) 37, to balance scientific and economic analysis and value-based judgements of generally acceptable risk in prescribing decisions. For a given course of antibiotics, the model balances the expected benefit (i.e., greater chance of survival) and the expected costs, including the dollar amount of a drug, its side effects, its contribution to future resistance, and even its effect on the mortality of other community members, including future generations 37. Moral decisions about costs of reduced quality of life and the value of life for present and future patients underpin the TREAT model 37. Without such models, the true cost of antibiotics will go unheeded. Antibiotics are not benign medications and their risks need to be fully accounted for and discussed with patients. Public and scientific discourse to determine who should receive treatment would be necessary to generate ethical guidelines for antibiotic use 38,39.

In the meantime, antibiotic stewardship programs (ASPs) have already been successful at optimizing patient outcomes while minimizing toxicity, costs, and the potential for microbial resistance within hospitals 40,41. ASPs are coordinated programs led by an infectious disease physician and a pharmacist that promote appropriate antibiotic use, reduce microbial resistance, and improve patient outcomes. We traditionally think about stewardship in the context of antibiotics. However, as we develop a greater understanding of the ecotoxicity of other pharmaceuticals and their impacts on public health, the principles of stewardship applied to antibiotics might prove useful for other pharmaceuticals. The Choosing Wisely® campaign uses this stewardship framework 42. Sponsored by the American Board of Internal Medicine and Consumer Reports, Choosing Wisely asks medical societies to publish five tests or interventions performed inappropriately 42. The campaign also promotes conversations between patients and clinicians about these tests 42. Sweden and the European Union have categorized drugs according to environmental risk to guide prescribers and institutions 43, and this data could be incorporated into existing prescribing models.

Conclusion

Mr. Johnson's case highlights the tension between protecting an individual and minimizing harm to water sources and public health. While the environmental and public health consequences are clear, the ethical question of whether and how they should influence prescribing practices remains unresolved. Prescribers should cultivate greater environmental awareness of the fate of pharmaceuticals through medical education and through institutional and policy-level interventions such as the TREAT model, ASPs, and the Choosing Wisely campaign. These programs would also help identify appropriate prescribing habits and which antibiotics have the most benign environmental profile. We need continued research to identify sites and quantities of pharmaceutical release in aquatic environments and their impact on human and environmental health. As the influence of environmental degradation on human health becomes increasingly clear, the health care community needs to examine its roles in current environmental contamination trends and work towards creating a healthier planet for all of us.

Sign in to take quiz and track your certificates

Article Information

AMA Journal of Ethics

AMA J Ethics. 2017;19(10):957-965.

AMA CME Accreditation Information

The American Medical Association designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclaimer: The people and events in this case are fictional. Resemblance to real events or to names of people, living or dead, is entirely coincidental. The viewpoints expressed in this article are those of the author(s) and do not necessarily reflect the views and policies of the AMA.

Author Information:

  • Jeremy Balch is a fourth-year medical student at the University of Michigan in Ann Arbor. He is interested in pursuing an academic career in medicine that focuses on health policy and its impact on our environment and society; Julia H. Schoen, MS is a fourth-year medical student at the University of Michigan in Ann Arbor with a master of science degree in environmental engineering. She is interested in bioethics as well as the intersection between environmental issues and medicine; Payal K. Patel, MD, MPH is the medical director of antimicrobial stewardship at the Veterans Affairs Ann Arbor Healthcare System in Ann Arbor, Michigan. She is also an assistant professor of infectious diseases at the University of Michigan. Her research and scholarship focus on innovative approaches to antimicrobial stewardship.

Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships.

References
REFERENCES
1.
American Medical Association.  Opinion 8.1 Routine universal screening for HIV.  Code of Medical Ethics. https://www.ama-assn.org/sites/default/files/media-browser/code-of-medical-ethics-chapter-8.pdf. Published 2016. Accessed August 10, 2017.Google Scholar
2.
American Medical Association.  Opinion 8.4 Ethical use of quarantine and isolation.  Code of Medical Ethics. https://www.ama-assn.org/sites/default/files/media-browser/code-of-medical-ethics-chapter-8.pdf. Published 2016. Accessed August 10, 2017.Google Scholar
3.
American Medical Association.  Opinion 8.10 Preventing, identifying and treating violence and abuse.  Code of Medical Ethics. https://www.ama-assn.org/sites/default/files/media-browser/code-of-medical-ethics-chapter-8.pdf. Published 2016. Accessed August 10, 2017.Google Scholar
4.
Ankley  GT, Brooks  BW, Huggett  DB, Sumpter  JP.  Repeating history: pharmaceuticals in the environment.  Environ Sci Technol. 41(24):8211-8217.Google ScholarCrossref
5.
Kümmerer  K.  Resistance in the environment.  J Antimicrob Chemother. 2004;54(2):311-320.Google ScholarCrossref
6.
Lesher  GY, Froelich  EJ, Gruett  MD, Bailey  JH, Brundage  RP.  1,8-naphthyridine derivatives. A new class of chemotherapeutic agents.  J Med Pharm Chem. 1962;911063-1065.Google Scholar
7.
 Pharmaceutical manufacturing point source category, 40 CFR sec 439  (2004). https://www.gpo.gov/fdsys/pkg/CFR-2004-title40-vol28/pdf/CFR-2004-title40-vol28-part439.pdf. Accessed August 17, 2017.
8.
Kolpin  DW, Furlong  ET, Meyer  MT  et al.  Pharmaceuticals, hormones, and other organic wastewater contaminants in US streams, 1999-2000: a national reconnaissance.  Environ Sci Technol. 2002;36(6):1202-1211.Google ScholarCrossref
9.
Harris  G.  Concerns grow in the US over drugs made abroad.  New York Times. January20 , 2009. http://www.nytimes.com/2009/01/20/business/worldbusiness/20iht-drug.1.19514627.html. Accessed April 30, 2017.Google Scholar
10.
 Securing the Pharmaceutical Supply Chain: Hearings Before the Senate Committee on Health, Education, Labor and Pensions, 112th Cong, 1st Sess (2011) (testimony of Deborah M. Autor, FDA deputy commissioner for Global Regulatory Operations and Policy).https://wayback.archive-it.org/7993/20170406161719/https://www.fda.gov/NewsEvents/Testimony/ucm271073.htm. Accessed August 17, 2017.
11.
Larsson  DGJ, de Pedro  C, Paxeus  N.  Effluent from drug manufactures contains extremely high levels of pharmaceuticals.  J Hazard Mater. 2007;148(3):751-755.Google ScholarCrossref
12.
Lübbert  C, Baars  C, Dayakar  A  et al.  Environmental pollution with antimicrobial agents from bulk drug manufacturing industries in Hyderabad, South India, is associated with dissemination of extended-spectrum beta-lactamase and carbapenemase-producing pathogens.  Infection. 2017;45(4):479-491.Google ScholarCrossref
13.
Walsh  TR, Weeks  J, Livermore  DM, Toleman  MA.  Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study.  Lancet Infect Dis. 2011;11(5):355-362.Google ScholarCrossref
14.
Practice Greenhealth.  Managing pharmaceutical waste: a 10-step blueprint for healthcare facilities in the United States. http://www.hercenter.org/hazmat/tenstepblueprint.pdf. Published 2006. Revised August 2008. Accessed August 17, 2017.
15.
DynaMed Plus.  Ciprofloxacin. http://www.dynamed.com/topics/dmp~AN~T908249/Ciprofloxacin.Published 2015. Updated August 7, 2017. Accessed August 17, 2017.
16.
Verlicchi  P, Al Aukidy  M, Galletti  A, Petrovic  M, Barceló  D.  Hospital effluent: investigation of the concentrations and distribution of pharmaceuticals and environmental risk assessment.  Sci Total Environ. 2012;430:109-118.Google ScholarCrossref
17.
Verlicchi  P, Al Aukidy  M, Zambello  E.  Occurrence of pharmaceutical compounds in urban wastewater: removal, mass load and environmental risk after a secondary treatment—a review.  Sci Total Environ. 2012;429:123-155.Google ScholarCrossref
18.
Bréchet  C, Plantin  J, Sauget  M  et al.  Wastewater treatment plants release large amounts of extended-spectrum beta-lactamase-producing Escherichia coli into the environment.  Clin Infect Dis. 2014;58(12):1658-1665.Google ScholarCrossref
19.
Caplin  JL, Hanlon  GW, Taylor  HD.  Presence of vancomycin and ampicillin-resistant Enterococcus faecium of epidemic clonal complex-17 in wastewaters from the south coast of England.  Environ Microbiol. 2008;10(4):885-892.Google ScholarCrossref
20.
Rodriguez-Mozaz  S, Chamorro  S, Marti  E  et al.  Occurrence of antibiotics and antibiotic resistance genes in hospital and urban wastewaters and their impact on the receiving river.  Water Res. 2015;69234-242.Google Scholar
21.
Varela  AR, Ferro  G, Vredenburg  J  et al.  Vancomycin resistant enterococci: from the hospital effluent to the urban wastewater treatment plant.  Sci Total Environ. 2013;450-451155-161.Google Scholar
22.
Verlicchi  P, Galletti  A, Petrovic  M, Barceló  D.  Hospital effluents as a source of emerging pollutants: an overview of micropollutants and sustainable treatment options.  J Hydrol. 2010;389(3-4):416-428.Google ScholarCrossref
23.
Zhang  Y, Marrs  CF, Simon  C, Xi  C.  Wastewater treatment contributes to selective increase of antibiotic resistance among Acinetobacter spp.  Sci Total Environ. 2009;407(12):3702-3706.Google ScholarCrossref
24.
Berglund  B.  Environmental dissemination of antibiotic resistance genes and correlation to anthropogenic contamination with antibiotics.  Infect Ecol Epidemiol. 2015;5:28564. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4565060/. Accessed August 17, 2017.Google Scholar
25.
Kothari  C, Gaind  R, Singh  LC  et al.  Community acquisition of beta-lactamase producing Enterobacteriaceae in neonatal gut.  BMC Microbiol. 2013;13:136. https://bmcmicrobiol.biomedcentral.com/articles/10.1186/1471-2180-13-136. Accessed August 28, 2017.Google Scholar
26.
Roose-Amsaleg  C, Laverman  AM.  Do antibiotics have environmental side-effects? Impact of synthetic antibiotics on biogeochemical processes.  Environ Sci Pollut Res Int. 2016;23(5):4000-4012.Google ScholarCrossref
27.
Crane  M, Watts  C, Boucard  T.  Chronic aquatic environmental risks from exposure to human pharmaceuticals.  Sci Total Environ. 2006;367(1):23-41.Google ScholarCrossref
28.
Jones  OAH, Voulvoulis  N, Lester  JN.  Aquatic environmental assessment of the top 25 English prescription pharmaceuticals.  Water Res. 2002;36(20):5013-5022.Google ScholarCrossref
29.
Fent  K, Weston  AA, Caminada  D.  Ecotoxicology of human pharmaceuticals.  Aquat Toxicol. 2006;76(2):122-159.Google ScholarCrossref
30.
Whitmee  S, Haines  A, Beyrer  C  et al.  Safeguarding human health in the anthropocene epoch: report of the Rockefeller Foundation—Lancet Commission on planetary health.  Lancet. 0205;386(10007):1973-2028.Google ScholarCrossref
31.
Kuhse  H, Singer  P, eds.  A Companion to Bioethics. New York, NY: John Wiley and Sons; 2013.
32.
Potter  VR.  Bioethics, the science of survival.  Perspect Biol Med. 1970;14(1):127-153.Google ScholarCrossref
33.
Gruen  L, Ruddick  W.  Biomedical and environmental ethics alliance: common causes and grounds.  J Bioeth Inq. 2009;6(4):457-466.Google ScholarCrossref
34.
Kumar  A, Roberts  D, Wood  KE  et al.  Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. 2006;34(6):1589-1596.
35.
US Food and Drug Administration.  FDA briefing document: the benefits and risks of systemic fluoroquinolone antibacterial drugs for the treatment of acute bacterial sinusitis (ABS), acute bacterial exacerbation of chronic bronchitis in patients who have chronic obstructive pulmonary disease (ABECB-COPD), and uncomplicated urinary tract infections (uUTI). https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anti-infectivedrugsadvisorycommittee/ucm467383.pdf. Published November5 , 2015. Access June 10, 2017.
36.
Center for Disease Control and Prevention.  Measuring outpatient antibiotic prescribing. https://www.cdc.gov/getsmart/community/programs-measurement/measuring-antibiotic-prescribing.html. Updated March22 , 2017. Accessed June 3, 2017.
37.
Leibovici  L, Paul  M, Andreassen  S.  Balancing the benefits and costs of antibiotic drugs: the TREAT model.  Clinical Microbiol Infect. 2010;16(12):1736-1739.Google ScholarCrossref
38.
Shaw  DM, Rich  LE.  Intergenerational global heath.  J Bioeth Inq. 2015;12(1):1-4.Google ScholarCrossref
39.
Leibovici  L, Paul  M.  Ethical dilemmas in antibiotic treatment: focus on the elderly.  Clin Microbiol Infect. 2015;21(1):27-29.Google ScholarCrossref
40.
Patel  PK, Srinivasan  A.  Moving antibiotic stewardship from theory to practice.  J Hosp Med. 2017;12(5):382-383.Google ScholarCrossref
41.
Patel  PK.  Applying the horizontal and vertical paradigm to antimicrobial stewardship.  Infect Control Hosp Epidemiol. 2017;38(5):532-533.Google ScholarCrossref
42.
Wolfson  D, Santa  J, Slass  L.  Engaging physicians and consumers in conversations about treatment overuse and waste: a short history of the Choosing Wisely campaign.  Acad Med. 2014;89(7):990-995.Google ScholarCrossref
43.
Stockholm County Council.  Environmentally classified pharmaceuticals. http://www.janusinfo.se/Global/Miljo_och_lakemedel/Miljobroschyr_2014_engelsk_webb.pdf.Published January2014. Accessed June 11, 2017.

Name Your Search

Save Search

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

Topics
State Requirements